The Movement Disorder Society has included safinamide in a different class from selegiline and rasagiline because of its different mechanism of action: MAO-B/glutamate release inhibitor, even though they belong to the same therapeutic class of MAO inhibitors. Here, MAOB is linked to movement disorder.